-DOCSTART-	
	
Familial	B-Process
amyloidotic	I-Process
polyneuropathy	I-Process
(	I-Process
FAP	I-Process
)	I-Process
is	O
a	B-Process
hereditary	I-Process
amyloidosis	I-Process
induced	B-Process
by	O
amyloidogenic	B-Material
transthyretin	I-Material
(	I-Material
ATTR	I-Material
)	I-Material
.	O
	
Because	O
most	B-Material
transthyretin	I-Material
(	I-Material
TTR	I-Material
)	I-Material
in	I-Material
serum	I-Material
is	O
synthesized	B-Process
by	O
the	B-Material
liver	I-Material
,	O
liver	B-Process
transplantation	I-Process
(	I-Process
LT	I-Process
)	I-Process
is	O
today	O
the	O
only	O
treatment	O
available	O
to	O
halt	B-Process
the	B-Process
progression	I-Process
of	I-Process
FAP	I-Process
,	O
even	O
though	O
LT	B-Process
is	O
associated	O
with	O
several	B-Process
problems	I-Process
.	O
	
Despite	O
the	O
urgent	O
need	O
to	O
develop	O
alternatives	O
to	O
LT	B-Process
,	O
the	B-Data
detailed	I-Data
pathogenesis	I-Data
of	O
FAP	B-Process
is	O
still	O
unknown	O
;	O
also	O
,	O
no	O
model	O
fully	O
represents	O
the	B-Process
relevant	I-Process
processes	I-Process
in	O
patients	B-Material
with	O
FAP	B-Process
.	O
	
The	B-Process
induction	I-Process
of	O
induced	B-Material
pluripotent	I-Material
stem	I-Material
(	I-Material
iPS	I-Material
)	I-Material
cells	I-Material
has	O
allowed	O
development	B-Process
of	O
pluripotent	B-Material
cells	I-Material
specific	O
for	O
patients	B-Material
and	O
has	O
led	O
to	O
useful	B-Material
models	I-Material
of	O
human	B-Process
diseases	I-Process
.	O
	
Because	O
of	O
the	O
need	O
for	O
a	O
tool	O
to	O
elucidate	B-Process
the	B-Data
molecular	I-Data
pathogenesis	I-Data
of	O
FAP	B-Process
,	O
in	O
this	O
study	O
we	O
sought	O
to	O
establish	O
heterozygous	B-Material
ATTR	I-Material
mutant	I-Material
iPS	I-Material
cells	I-Material
,	O
and	O
were	O
successful	O
,	O
by	O
using	O
a	B-Material
Sendai	I-Material
virus	I-Material
vector	I-Material
mixture	I-Material
containing	O
four	B-Material
transcription	I-Material
factors	I-Material
(	I-Material
Oct3/4	I-Material
,	I-Material
Sox2	I-Material
,	I-Material
Klf4	I-Material
,	I-Material
and	I-Material
c	I-Material
-	I-Material
Myc	I-Material
)	I-Material
to	O
reprogram	B-Process
dermal	B-Material
fibroblasts	I-Material
derived	B-Process
from	O
FAP	B-Material
patients	I-Material
.	O
	
Moreover	O
,	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
had	O
the	O
potential	O
to	O
differentiate	B-Process
into	O
hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
and	O
indeed	O
expressed	B-Material
ATTR	I-Material
.	O
	
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
demonstrated	O
the	O
possibility	O
of	O
serving	O
as	O
a	B-Method
pathological	I-Method
tool	I-Method
that	O
will	O
contribute	O
to	O
understanding	O
the	B-Data
pathogenesis	I-Data
of	O
FAP	B-Process
and	O
development	O
of	O
FAP	B-Process
treatments	I-Process
.	O
	
Highlights	O
•	O
	
We	O
established	O
,	O
for	O
the	O
first	O
time	O
,	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
by	O
using	O
a	B-Material
Sendai	I-Material
virus	I-Material
.	O
	
•	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
have	O
potential	O
to	O
differentiate	B-Process
into	O
hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
.	O
	
•	O
	
Hepatocyte	B-Material
-	I-Material
like	I-Material
cells	I-Material
from	O
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
indeed	O
expressed	B-Material
ATTR	I-Material
Val30Met	I-Material
.	O
	
•	O
	
FAP	B-Material
-	I-Material
specific	I-Material
iPS	I-Material
cells	I-Material
demonstrate	O
the	O
possibility	O
to	O
serve	O
as	O
a	B-Material
pathological	I-Material
tool	I-Material
.	O
	
